Clinical outcomes of combined versus separate carbachol and brimonidine drops in correcting presbyopia
| Autor: | Almamoun Abdelkader, Herbert E. Kaufman |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Miosis
medicine.medical_specialty Depth of focus Binocular distance Carbachol Distance visual acuity genetic structures Emmetropia Pupil 03 medical and health sciences 0302 clinical medicine Ophthalmology medicine business.industry Brimonidine Research Presbyopia medicine.disease eye diseases 030221 ophthalmology & optometry medicine.symptom business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Eye and Vision |
| ISSN: | 2326-0254 1261-6001 |
| Popis: | To test and compare in a masked fashion the efficacy of using a parasympathomimetic drug (3% carbachol) and an alpha-2 agonist (0.2% brimonidine) in both combined and separate forms to create optically beneficial miosis to pharmacologically improve vision in presbyopia. A prospective, double-masked, randomized, controlled clinical trial was conducted. Ten naturally emmetropic and presbyopic subjects between 42 and 58 years old with uncorrected distance visual acuity of at least 20/20 in both eyes without additional ocular pathology were eligible for inclusion. All subjects received 3% carbachol and 0.2% brimonidine in both combined and separate forms, 3% carbachol alone and 0.2% brimonidine (control) alone in their non-dominant eye in a crossover manner with one week washout between tests. The subjects’ pupil sizes and both near and distance visual acuities will be evaluated pre- and post-treatment at 1, 2, 4, and 8 h, by a masked examiner at the same room illumination. Statistically significant improvement in mean near visual acuity (NVA) was achieved in all subjects who received combined 3% carbachol and 0.2% brimonidine in the same formula compared with those who received separate forms or carbachol alone or brimonidine alone (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink